Compare ILMN & MDLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILMN | MDLN |
|---|---|---|
| Founded | 1998 | 1966 |
| Country | United States | United States |
| Employees | 8650 | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0B | 31.0B |
| IPO Year | 2000 | 2025 |
| Metric | ILMN | MDLN |
|---|---|---|
| Price | $238.46 | $31.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 23 |
| Target Price | ★ $124.24 | $50.48 |
| AVG Volume (30 Days) | 2.0M | ★ 6.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.87 | N/A |
| EPS | ★ 2.22 | 0.23 |
| Revenue | $4,343,000,000.00 | ★ $28,432,000,000.00 |
| Revenue This Year | $6.47 | $10.88 |
| Revenue Next Year | $5.58 | $7.69 |
| P/E Ratio | ★ $110.44 | $139.65 |
| Revenue Growth | N/A | ★ 11.47 |
| 52 Week Low | $88.00 | $31.63 |
| 52 Week High | $246.76 | $50.88 |
| Indicator | ILMN | MDLN |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 36.88 |
| Support Level | $116.43 | N/A |
| Resistance Level | N/A | $37.39 |
| Average True Range (ATR) | 9.25 | 1.31 |
| MACD | 2.28 | -0.19 |
| Stochastic Oscillator | 77.18 | 7.01 |
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.